These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

238 related articles for article (PubMed ID: 23408515)

  • 21. Adjuvant sorafenib reduced mortality and prolonged overall survival and post-recurrence survival in hepatocellular carcinoma patients after curative resection: a single-center experience.
    Zhang W; Zhao G; Wei K; Zhang Q; Ma W; Song T; Wu Q; Zhang T; Kong D; Li Q
    Biosci Trends; 2014 Dec; 8(6):333-8. PubMed ID: 25641180
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinical analysis of patients with hepatocellular carcinoma recurrence after living-donor liver transplantation.
    Na GH; Hong TH; You YK; Kim DG
    World J Gastroenterol; 2016 Jul; 22(25):5790-9. PubMed ID: 27433092
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Adverse events affect sorafenib efficacy in patients with recurrent hepatocellular carcinoma after liver transplantation: experience at a single center and review of the literature.
    Zavaglia C; Airoldi A; Mancuso A; Vangeli M; Viganò R; Cordone G; Gentiluomo M; Belli LS
    Eur J Gastroenterol Hepatol; 2013 Feb; 25(2):180-6. PubMed ID: 23044808
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Hepatocellular carcinoma cases with high levels of c-Raf-1 expression may benefit from postoperative adjuvant sorafenib after hepatic resection even with high risk of recurrence.
    Lei J; Zhong J; Hao J; Liu Z; Zhang P; Wu L; Yan L; Zhu J; Zeng Y; Li B; Wen T; Wang W
    Oncotarget; 2016 Jul; 7(27):42598-42607. PubMed ID: 26981887
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Everolimus augments the effects of sorafenib in a syngeneic orthotopic model of hepatocellular carcinoma.
    Piguet AC; Saar B; Hlushchuk R; St-Pierre MV; McSheehy PM; Radojevic V; Afthinos M; Terracciano L; Djonov V; Dufour JF
    Mol Cancer Ther; 2011 Jun; 10(6):1007-17. PubMed ID: 21487053
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Recurrent hepatocellular carcinoma after liver transplantation - an emerging clinical challenge.
    Welker MW; Bechstein WO; Zeuzem S; Trojan J
    Transpl Int; 2013 Feb; 26(2):109-18. PubMed ID: 22994652
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Iron-dependent cell death of hepatocellular carcinoma cells exposed to sorafenib.
    Louandre C; Ezzoukhry Z; Godin C; Barbare JC; Mazière JC; Chauffert B; Galmiche A
    Int J Cancer; 2013 Oct; 133(7):1732-42. PubMed ID: 23505071
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Adjuvant treatment of hepatocellular carcinoma after orthotopic liver transplantation: do we really need this?
    Fujiki M; Aucejo F; Kim R
    Clin Transplant; 2013; 27(2):169-77. PubMed ID: 23216662
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Rho-kinase-dependent pathway mediates the hepatoprotective effects of sorafenib against ischemia/reperfusion liver injury in rats with nonalcoholic steatohepatitis.
    Yang YY; Huang YT; Lee TY; Chan CC; Yeh YC; Lee KC; Lin HC
    Liver Transpl; 2012 Nov; 18(11):1371-83. PubMed ID: 22847887
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Radiosensitivity enhancement of human hepatocellular carcinoma cell line SMMC-7721 by sorafenib through the MEK/ERK signal pathway.
    Dai XF; Ding J; Zhang RG; Ren JH; Ma CM; Wu G
    Int J Radiat Biol; 2013 Sep; 89(9):724-31. PubMed ID: 23682582
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Sorafenib attenuates monocrotaline-induced sinusoidal obstruction syndrome in rats through suppression of JNK and MMP-9.
    Nakamura K; Hatano E; Narita M; Miyagawa-Hayashino A; Koyama Y; Nagata H; Iwaisako K; Taura K; Uemoto S
    J Hepatol; 2012 Nov; 57(5):1037-43. PubMed ID: 22796153
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effect of rapamycin alone and in combination with sorafenib in an orthotopic model of human hepatocellular carcinoma.
    Wang Z; Zhou J; Fan J; Qiu SJ; Yu Y; Huang XW; Tang ZY
    Clin Cancer Res; 2008 Aug; 14(16):5124-30. PubMed ID: 18698030
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Sorafenib use in the transplant setting.
    Castelli G; Burra P; Giacomin A; Vitale A; Senzolo M; Cillo U; Farinati F
    Liver Transpl; 2014 Sep; 20(9):1021-8. PubMed ID: 24809799
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Sorafenib enhances proteasome inhibitor-mediated cytotoxicity via inhibition of unfolded protein response and keratin phosphorylation.
    Honma Y; Harada M
    Exp Cell Res; 2013 Aug; 319(14):2166-78. PubMed ID: 23727131
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Sorafenib reduces hepatic infiltrated regulatory T cells in hepatocellular carcinoma patients by suppressing TGF-beta signal.
    Wang Q; Yu T; Yuan Y; Zhuang H; Wang Z; Liu X; Feng M
    J Surg Oncol; 2013 Mar; 107(4):422-7. PubMed ID: 22833259
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Monitoring anti-angiogenic therapy in colorectal cancer murine model using dynamic contrast-enhanced MRI: comparing pixel-by-pixel with region of interest analysis.
    Haney CR; Fan X; Markiewicz E; Mustafi D; Karczmar GS; Stadler WM
    Technol Cancer Res Treat; 2013 Feb; 12(1):71-8. PubMed ID: 22905809
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Extending survival with the use of targeted therapy in the treatment of hepatocellular carcinoma.
    Gish RG; Finn RS; Marrero JA
    Clin Adv Hematol Oncol; 2013 Apr; 11 Suppl 5():1-22; quiz 2 p following p22. PubMed ID: 23881427
    [TBL] [Abstract][Full Text] [Related]  

  • 38. TLR3 agonist and Sorafenib combinatorial therapy promotes immune activation and controls hepatocellular carcinoma progression.
    Ho V; Lim TS; Lee J; Steinberg J; Szmyd R; Tham M; Yaligar J; Kaldis P; Abastado JP; Chew V
    Oncotarget; 2015 Sep; 6(29):27252-66. PubMed ID: 26287667
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Serum C-reactive protein is a useful biomarker for predicting outcomes after liver transplantation in patients with hepatocellular carcinoma.
    An HJ; Jang JW; Bae SH; Choi JY; Yoon SK; Lee MA; You YK; Kim DG; Jung ES
    Liver Transpl; 2012 Dec; 18(12):1406-14. PubMed ID: 22821639
    [TBL] [Abstract][Full Text] [Related]  

  • 40. AZD6244 enhances the anti-tumor activity of sorafenib in ectopic and orthotopic models of human hepatocellular carcinoma (HCC).
    Huynh H; Ngo VC; Koong HN; Poon D; Choo SP; Toh HC; Thng CH; Chow P; Ong HS; Chung A; Goh BC; Smith PD; Soo KC
    J Hepatol; 2010 Jan; 52(1):79-87. PubMed ID: 19910069
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.